Literature DB >> 1511657

First phase insulin release in the non-obese diabetic mouse: correlation with insulitis, beta cell number and autoantibodies.

S Reddy1, W Liu, J M Thompson, N J Bibby, R B Elliott.   

Abstract

The ontogenic variation of beta cell function and its relationship with the degree of islet damage and levels of autoantibodies have been studied in the non-obese diabetic (NOD) mouse model. We conducted in vivo first phase insulin release (FPIR) in response to intravenous glucose and studied its correlation with the degree of insulitis, islet cell antibody (ICA) and insulin autoantibody (IAA) levels in female NOD mice cross-sectionally at days 40 (n = 19), 90 (n = 21), 150-160 (n = 21) and day 250 (n = 20). The mean +/- SEM FPIR values showed an age-related decline from day 40 (46.2 +/- 5.3 microU/ml) to day 150-160 (17.8 +/- 2.5 microU/ml) and then doubled at day 250 (34.5 +/- 5 microU/ml), while the mean +/- SEM insulitis scores increased progressively until day 150-160 (61.7 +/- 6.1%) and then declined slightly at day 250 to 50.2 +/- 6.2%. In female NOD mice with spontaneous diabetes (n = 4) and streptozotocin-induced diabetic Swiss mice (n = 5) FPIR was either absent or greatly attenuated. A statistically significant inverse correlation between FPIR and insulitis was found among NOD mice at days 90 (P = 0.02; r = -0.52) and 150-160 (P = 0.03; r = -0.48). However, no statistically significant correlation was observed at days 40 and 250. Morphometric techniques applied to day 150-160 pancreatic sections showed a statistically significant negative correlation between insulitis and beta cell number per unit area of islet tissue (P = 0.0001; r = - 0.75). At this age some islet beta cells showed different intensities of staining by immunofluorescence.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511657     DOI: 10.1016/0168-8227(92)90039-t

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  7 in total

Review 1.  Metabolic abnormalities in the pathogenesis of type 1 diabetes.

Authors:  Shuyao Zhang; Clayton E Mathews
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

2.  Contribution of different mechanisms to pancreatic beta-cell hyper-secretion in non-obese diabetic (NOD) mice during pre-diabetes.

Authors:  Kuo Liang; Wen Du; Wenzhen Zhu; Shuang Liu; Yeqing Cui; Haichen Sun; Bin Luo; Yanhong Xue; Lu Yang; Liangyi Chen; Fei Li
Journal:  J Biol Chem       Date:  2011-09-13       Impact factor: 5.157

3.  Biphasic decline of β-cell function with age in euglycemic nonobese diabetic mice parallels diabetes onset.

Authors:  Sirlene R Cechin; Omar Lopez-Ocejo; Darla Karpinsky-Semper; Peter Buchwald
Journal:  IUBMB Life       Date:  2015-06-22       Impact factor: 3.885

4.  Exendin-4 modulates diabetes onset in nonobese diabetic mice.

Authors:  Irene Hadjiyanni; Laurie L Baggio; Philippe Poussier; Daniel J Drucker
Journal:  Endocrinology       Date:  2007-12-06       Impact factor: 4.736

5.  IFN-γ receptor deficiency prevents diabetes induction by diabetogenic CD4+, but not CD8+, T cells.

Authors:  Zuoan Yi; Li Li; Alaina Garland; Qiuming He; Haidong Wang; Jonathan D Katz; Roland Tisch; Bo Wang
Journal:  Eur J Immunol       Date:  2012-08       Impact factor: 5.532

6.  Progressive erosion of β-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes.

Authors:  Diego Ize-Ludlow; Yaima L Lightfoot; Matthew Parker; Song Xue; Clive Wasserfall; Michael J Haller; Desmond Schatz; Dorothy J Becker; Mark A Atkinson; Clayton E Mathews
Journal:  Diabetes       Date:  2011-06-09       Impact factor: 9.461

7.  Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes.

Authors:  Clayton E Mathews; Song Xue; Amanda Posgai; Yaima L Lightfoot; Xia Li; Andrea Lin; Clive Wasserfall; Michael J Haller; Desmond Schatz; Mark A Atkinson
Journal:  Diabetes       Date:  2015-07-27       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.